Hormonal contraception concerns a large proportion of young women worldwide. Breast cancer is the leading cancer for women. The question if there is a risk or what is the level of the risk for breast cancer in women users of hormonal contraception is thus important. Benign breast diseases (BBDs) are also a condition of clinical concern rather frequent in young women. Studies show that combined contraception (COC) is associated with less BBD (fibroadenoma and fibrocystic disease) in observational studies. As a consequence, no contraindication exists to indicate COC in women with a BBD. However, it is not clear if in the case of atypical hyperplasia using a COC cannot constitute a risk for breast cancer, given the fact that COC can likely exert a promoter effect on precancerous lesions or occult cancers. Progestin can be indicated if COC is not tolerated with an increase in mastalgia, especially if FCD is severe. Long-term treatment with progestin has been reported to decrease the symptoms of FCD and, at high doses, to be associated with a lower risk of breast cancer in an observational study. The risk of breast cancer associated with COC, progestin contraceptive, and the levonorgestrel IUD (IUS) will be presented and discussed. Recommended contraception in women with breast cancer and breast cancer survivors is non-hormonal. The specific condition of BRCA carriers will be discussed.